Condizione: New. pp. 354.
EUR 43,49
Quantità: 1 disponibili
Aggiungi al carrelloCondizione: New. pp. 354.
EUR 43,77
Quantità: 1 disponibili
Aggiungi al carrelloCondizione: New. pp. 354.
Da: Basi6 International, Irving, TX, U.S.A.
Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.
Da: Romtrade Corp., STERLING HEIGHTS, MI, U.S.A.
Condizione: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
Da: SMASS Sellers, IRVING, TX, U.S.A.
Condizione: New. Brand New Original US Edition. Customer service! Satisfaction Guaranteed.
Da: ALLBOOKS1, Direk, SA, Australia
EUR 93,44
Quantità: 8 disponibili
Aggiungi al carrelloBrand new book. Fast ship. Please provide full street address as we are not able to ship to P O box address.
Lingua: Inglese
Editore: Demos Medical Publishing, LLC, 2010
ISBN 10: 1933864788 ISBN 13: 9781933864785
Da: Books Puddle, New York, NY, U.S.A.
Condizione: New. pp. 1024.
Lingua: Inglese
Editore: Springer Publishing Company, Incorporated, 2010
ISBN 10: 1933864788 ISBN 13: 9781933864785
Da: Better World Books, Mishawaka, IN, U.S.A.
Condizione: Very Good. Used book that is in excellent condition. May show signs of wear or have minor defects.
Condizione: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.
Condizione: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
Lingua: Inglese
Editore: Demos Medical Publishing, LLC, 2010
ISBN 10: 1933864788 ISBN 13: 9781933864785
Da: Majestic Books, Hounslow, Regno Unito
EUR 95,72
Quantità: 4 disponibili
Aggiungi al carrelloCondizione: New. pp. 1024.
Da: UK BOOKS STORE, London, LONDO, Regno Unito
EUR 94,07
Quantità: Più di 20 disponibili
Aggiungi al carrelloCondizione: New. Brand New! Fast Delivery This is an International Edition and ship within 24-48 hours. Deliver by FedEx and Dhl, & Aramex, UPS, & USPS and we do accept APO and PO BOX Addresses. Order can be delivered worldwide within 7-10 days and we do have flat rate for up to 2LB. Extra shipping charges will be requested if the Book weight is more than 5 LB. This Item May be shipped from India, United states & United Kingdom. Depending on your location and availability.
Da: ALLBOOKS1, Direk, SA, Australia
EUR 112,68
Quantità: 1 disponibili
Aggiungi al carrelloBrand new book. Fast ship. Please provide full street address as we are not able to ship to P O box address.
Lingua: Inglese
Editore: Demos Medical Publishing, LLC, 2010
ISBN 10: 1933864788 ISBN 13: 9781933864785
Da: Biblios, Frankfurt am main, HESSE, Germania
EUR 103,95
Quantità: 4 disponibili
Aggiungi al carrelloCondizione: New. pp. 1024.
Da: Llibreria Hispano Americana, Barcelona, B, Spagna
EUR 65,00
Quantità: 1 disponibili
Aggiungi al carrelloEncuadernación de tapa dura. Condizione: Muy bueno.
EUR 46,57
Quantità: 1 disponibili
Aggiungi al carrelloCondizione: Sehr gut. Zustand: Sehr gut | Seiten: 352 | Sprache: Englisch | Produktart: Bücher | from combining radiation with a molecular targeted agent ¿ namely cetuximab, a recombinant mouse/human chimeric monoclonal antibody against the Epidermal Growth Factor (EGF) receptor [4] Astsaturov, Cohen and Harari present a more indepth review of the biology of the EGF Receptor and its signaling pathway in Chap. 7 as a potential target in combination with fractionated radiotherap y for head and neck squamous cell carcinoma (HNSCC). A flurry of agents are under de velopment for targeting EGFR and in March 2006, the US Food and Drugs Administration approved cetuximab combined with radiation as a primary treatment option for patients with loco-regionally advanced HNSCC in whom chemoradiation therapy is deemed not to be an option. While blocking the EGF pathway during fractionated radiotherapy may seem an obvious strategy [5], the rationale for combining antiangiogenic and antivascular targeting agents with radiation may be less intuitive. However, recent research shows that there are several reasons why this could result in a therapeutic gain in practice. Chapter 8 is a review of this rapidly expanding field by Citrin and Camphausen. Targeted agents combined with radiation may offer new opportunities in the treatment of central nervous system malignancies, a tumor type where the outlook remains poor despite some recent progress [6]. Current attempts to overcome rad- tion resistance in these tumors on the basis of an improved understanding of their molecular biology are the topic of Chap. 9 by Chakravarti and Palanichamy.
Da: Books Puddle, New York, NY, U.S.A.
Condizione: New. pp. xvi + 344.
Da: Lucky's Textbooks, Dallas, TX, U.S.A.
Condizione: New.
EUR 102,30
Quantità: 5 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Radiation Oncology Advances | Søren M. Bentzen (u. a.) | Taschenbuch | xvi | Englisch | 2010 | Springer US | EAN 9781441942210 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.
EUR 164,17
Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: Brand New. reprint edition. 360 pages. 9.00x6.00x0.83 inches. In Stock.
Lingua: Inglese
Editore: Springer US, Springer US Nov 2010, 2010
ISBN 10: 1441942211 ISBN 13: 9781441942210
Da: buchversandmimpf2000, Emtmannsberg, BAYE, Germania
EUR 117,69
Quantità: 2 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Neuware -from combining radiation with a molecular targeted agent ¿ namely cetuximab, a recombinant mouse/human chimeric monoclonal antibody against the Epidermal Growth Factor (EGF) receptor [4] Astsaturov, Cohen and Harari present a more indepth review of the biology of the EGF Receptor and its signaling pathway in Chap. 7 as a potential target in combination with fractionated radiotherap y for head and neck squamous cell carcinoma (HNSCC). A flurry of agents are under de velopment for targeting EGFR and in March 2006, the US Food and Drugs Administration approved cetuximab combined with radiation as a primary treatment option for patients with loco-regionally advanced HNSCC in whom chemoradiation therapy is deemed not to be an option. While blocking the EGF pathway during fractionated radiotherapy may seem an obvious strategy [5], the rationale for combining antiangiogenic and antivascular targeting agents with radiation may be less intuitive. However, recent research shows that there are several reasons why this could result in a therapeutic gain in practice. Chapter 8 is a review of this rapidly expanding field by Citrin and Camphausen. Targeted agents combined with radiation may offer new opportunities in the treatment of central nervous system malignancies, a tumor type where the outlook remains poor despite some recent progress [6]. Current attempts to overcome rad- tion resistance in these tumors on the basis of an improved understanding of their molecular biology are the topic of Chap. 9 by Chakravarti and Palanichamy.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 352 pp. Englisch.
EUR 122,12
Quantità: 1 disponibili
Aggiungi al carrelloTaschenbuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - from combining radiation with a molecular targeted agent - namely cetuximab, a recombinant mouse/human chimeric monoclonal antibody against the Epidermal Growth Factor (EGF) receptor [4] Astsaturov, Cohen and Harari present a more indepth review of the biology of the EGF Receptor and its signaling pathway in Chap. 7 as a potential target in combination with fractionated radiotherap y for head and neck squamous cell carcinoma (HNSCC). A flurry of agents are under de velopment for targeting EGFR and in March 2006, the US Food and Drugs Administration approved cetuximab combined with radiation as a primary treatment option for patients with loco-regionally advanced HNSCC in whom chemoradiation therapy is deemed not to be an option. While blocking the EGF pathway during fractionated radiotherapy may seem an obvious strategy [5], the rationale for combining antiangiogenic and antivascular targeting agents with radiation may be less intuitive. However, recent research shows that there are several reasons why this could result in a therapeutic gain in practice. Chapter 8 is a review of this rapidly expanding field by Citrin and Camphausen. Targeted agents combined with radiation may offer new opportunities in the treatment of central nervous system malignancies, a tumor type where the outlook remains poor despite some recent progress [6]. Current attempts to overcome rad- tion resistance in these tumors on the basis of an improved understanding of their molecular biology are the topic of Chap. 9 by Chakravarti and Palanichamy.
EUR 198,58
Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: Brand New. reprint edition. 360 pages. 9.00x6.00x0.83 inches. In Stock.
Da: GreatBookPrices, Columbia, MD, U.S.A.
Condizione: New.
Da: Mispah books, Redhill, SURRE, Regno Unito
EUR 197,97
Quantità: 1 disponibili
Aggiungi al carrelloPaperback. Condizione: Like New. Like New. book.
Lingua: Inglese
Editore: Springer Distribution Center GmbH (SDC), 2007
ISBN 10: 0387367438 ISBN 13: 9780387367439
Da: Libro Co. Italia Srl, San Casciano Val di Pesa, FI, Italia
EUR 197,59
Quantità: 1 disponibili
Aggiungi al carrelloBrossura. Condizione: fine. Heidelberg, 2007; pp. 341. Libro.
Da: GreatBookPrices, Columbia, MD, U.S.A.
Condizione: As New. Unread book in perfect condition.
EUR 166,62
Quantità: 1 disponibili
Aggiungi al carrelloBuch. Condizione: Neu. Druck auf Anfrage Neuware - Printed after ordering - from combining radiation with a molecular targeted agent - namely cetuximab, a recombinant mouse/human chimeric monoclonal antibody against the Epidermal Growth Factor (EGF) receptor [4] Astsaturov, Cohen and Harari present a more indepth review of the biology of the EGF Receptor and its signaling pathway in Chap. 7 as a potential target in combination with fractionated radiotherap y for head and neck squamous cell carcinoma (HNSCC). A flurry of agents are under de velopment for targeting EGFR and in March 2006, the US Food and Drugs Administration approved cetuximab combined with radiation as a primary treatment option for patients with loco-regionally advanced HNSCC in whom chemoradiation therapy is deemed not to be an option. While blocking the EGF pathway during fractionated radiotherapy may seem an obvious strategy [5], the rationale for combining antiangiogenic and antivascular targeting agents with radiation may be less intuitive. However, recent research shows that there are several reasons why this could result in a therapeutic gain in practice. Chapter 8 is a review of this rapidly expanding field by Citrin and Camphausen. Targeted agents combined with radiation may offer new opportunities in the treatment of central nervous system malignancies, a tumor type where the outlook remains poor despite some recent progress [6]. Current attempts to overcome rad- tion resistance in these tumors on the basis of an improved understanding of their molecular biology are the topic of Chap. 9 by Chakravarti and Palanichamy.
Da: Revaluation Books, Exeter, Regno Unito
EUR 238,03
Quantità: 2 disponibili
Aggiungi al carrelloHardcover. Condizione: Brand New. 1st edition. 341 pages. 9.25x6.25x0.75 inches. In Stock.